TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7926977
Drug: Recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant erythropoietin (r‐EPO) administered subcutaneously at dosages up to 1050 U/kg a week for at least two months
Study: 2512637
Drug: tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tenoxicam 20 mg daily
Study: 2512637
Drug: piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: piroxicam 20 mg daily
Study: 1105630
Drug: Secobarbital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital (100 mg)
Study: 1105630
Drug: Secobarbital (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital (130 mg)
Study: 1105630
Drug: CPZ (0.667
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPZ (0.667 and 1.334 mg/kg)
Study: 1105630
Drug: Diazepam (0.071,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.071, 0.142, and 0.284 mg/kg)
Study: 27109623
Drug: Verucerfont (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verucerfont (350 mg per day)
Study: 19954391
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream
Study: 16503881
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual care with emollients and topical corticosteroids)
Study: 12788302
Drug: Repeat fibrinolytic
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat fibrinolytic therapy
Study: 12788302
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment (repeat fibrinolysis or urgent revascularization)
Study: 6845046
Drug: Benzoylmetronidazole 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoylmetronidazole 50 ml (2 g metronidazole equivalent) as a single dose
Study: 25315942
Drug: Esmolol (β-blocker)
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol (β-blocker)
Study: 27485803
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine injection
Study: 10670862
Drug: Open carotid
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open carotid endarterectomy with patch closure (CEAP)
Study: 7587688
Drug: Preoperative parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative parenteral nutritional support (PNS) for 7 days in addition to oral intake
Study: 7587688
Drug: Preoperative parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative parenteral nutritional support (PNS)
Study: 43488
Drug: Oxprenolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (300 mg daily for 8 weeks)
Study: 43488
Drug: Beta-blocking agents
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocking agents alone
Study: 43488
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of oxprenolol and clortalidone
Study: 43488
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of oxprenolol and phentolamine
Study: 24721352
Drug: Penehyclidine inhalation
Normalized name: Penequinine, Penehyclidine
DrugBank: Penequinine, Penehyclidine (DB16287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine inhalation
Study: 31135570
Drug: VYC‐25L hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: VYC‐25L hyaluronic acid injectable gel
Study: 26938764
Drug: Dexamethasone with
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone with bupivacaine (8 mg dexamethasone mixed with 18 mL of 0.25% bupivacaine)
Study: 26938764
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with placebo (18 mL of 0.25% bupivacaine and 2 mL of 0.9% saline)
Study: 23841261
Drug: Sarcandra glabra
Normalized name: SARCANDRA GLABRA TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcandra glabra (SG) decoction at a daily dose of 20 g
Study: 15100562
Drug: Adherents to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherents to stimulant treatment (n = 41)
Study: 15100562
Drug: Adherents to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherents to stimulant treatment (n = 16)
Study: 15100562
Drug: Medication status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication status at year 2
Study: 15100562
Drug: Adverse effects
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse effects of stimulant treatment
Study: 8512622
Drug: Low-dose ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose ethanol (LD)
Study: 8512622
Drug: High-dose ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose ethanol (HD)
Study: 17121049
Drug: TCM syndrome-typing
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM syndrome-typing based therapy (TCM-STBT) combined with cyclosporin
Study: 12505967
Drug: Torque control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torque control blocker Univent (Group B)
Study: 12505967
Drug: Wire-guided Arndt
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wire-guided Arndt blocker (Group C)
Study: 11276182
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy interventions with visual biofeedback/forceplate training
Study: 11276182
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy interventions without visual biofeedback/forceplate training (Control)
Study: 9250745
Drug: Indomethacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (2 x 50 mg for 7 days)
Study: 9250745
Drug: Indomethacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (2 x 50 mg for 14 days)
Study: 8237989
Drug: Schwarz standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz standard measles vaccine
Study: 8237989
Drug: High-titer Edmonston-Zagreb
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer Edmonston-Zagreb or Schwarz vaccines
Study: 29098470
Drug: SBM supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBM supplement (SBMS) diet (with Lys and Met supplementation)
Study: 16551966
Drug: Cladribine combined
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine combined with cyclophosphamide (CC)
Study: 12666705
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser treatment (100 mj, 20 pps, 2.0 W, 120 seconds)
Study: 12666705
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser treatment (2.0 W, 120 seconds)
Study: 8694299
Drug: Fenoterol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (600 micrograms via metered-dose inhaler, 3 puffs 10 min before induction)
Study: 8694299
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 puffs of aerosol containing no medication)
Study: 29555457
Drug: NP education
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP education plus tablet application (interactive conditional logic program)
Study: 26283035
Drug: Belagenpumatucel-L
Normalized name: Belagenpumatucel-L (RH 2)
DrugBank: Belagenpumatucel-L (SK-LU-1) (DB17402)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belagenpumatucel-L
Study: 23677353
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of rhBMP-2
Study: 23677353
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of autologous bone
Study: 15828972
Drug: Concurrent distracting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent distracting mental activity (e.g., free-associating on a task-irrelevant theme or listening to music)
Study: 15828972
Drug: No concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concurrent distracting mental activity (control condition)
Study: 1771935
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg roxatidine nocte
Study: 8150836
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream
Study: 25828637
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of etoposide
Study: 21214708
Drug: Ketamine 2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2.2 mg kg(‐1) IV
Study: 21214708
Drug: Alfaxalone 1
Normalized name: alfaxalone 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 1 mg kg(‐1) IV
Study: 23919898
Drug: Risperidone (3-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (3-12 mg/day)
Study: 19553086
Drug: Quetiapine (300-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (300-750 mg/day)
Study: 19553086
Drug: Aripiprazole (12-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (12-30 mg/day)
Study: 15547527
Drug: Metformin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500 mg daily)
Study: 9213716
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (17 g MgSO4 in 1000 ml isotonic saline)
Study: 1909083
Drug: Fluvoxamine (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100-200 mg daily)
Study: 1909083
Drug: Mianserin (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (40-80 mg daily)
Study: 6343041
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (Novo)
Study: 2870943
Drug: Purified pork
Normalized name: Insulin purified pork
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purified pork insulin
Study: 31574899
Drug: Animal-Assisted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-Assisted Therapy (AAT) with the presence of a dog during a break (Condition C)
Study: 30931588
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri (2 probiotic tablets 2× per day for 21 days)
Study: 9878012
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg famciclovir
Study: 25542064
Drug: Placebo (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (125 mg)
Study: 9878012
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg famciclovir
Study: 20489689
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) high-dose
Study: 16680253
Drug: Diclofenac (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (1 mg x kg(‐1) intramuscular) + remifentanil (0.1 microg x kg(‐1)min(‐1)) + ketamine (0.8 mg x kg(‐1) intravenously)
Study: 16680253
Drug: Remifentanil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.1 microg x kg(‐1)min(‐1)) + ketamine (0.8 mg x kg(‐1) intravenously)
Study: 11523155
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care (tooth brushing after each meal and daily oropharyngeal scrubbing with 1% povidone iodine)
Study: 11523155
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral care (provided by dentists or dental hygienists once a week)
Study: 9020273
Drug: Deltibant (CP-0127)
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deltibant (CP-0127) 0.3, 1.0, or 3.0 microg x kg(‐1) x min(‐1) continuous intravenous infusion
Study: 7942581
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) 2 g/d
Study: 2833920
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and lisinopril
Study: 2833920
Drug: Nifedipine and
Normalized name: nifedipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine and Lisinopril
Study: 30341961
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (6 mm; GS)
Study: 30341961
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants (11-15 mm; GG)
Study: 26902851
Drug: all treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: all treatment arms
Study: 24013981
Drug: Comparator treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator treatments (oral antidiabetic drugs, dietary changes, or other insulins)
Study: 24013981
Drug: Comparator treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator treatments
Study: 24288511
Drug: Treatment (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (not specified in detail)
Study: 20484612
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 40-mg dose of laropiprant (LRPT)
Study: 8820475
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.5 g omega‐3 fatty acids/day)
Study: 20136971
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection therapy
Study: 1427365
Drug: Heater probe
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heater probe therapy
Study: 6994084
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg at bedtime or twice daily for up to 12 months
Study: 16750703
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (including atorvastatin)
Study: 14658972
Drug: Mirtazapine (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15-45 mg/day)
Study: 2106277
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate hypoosmolar solution (40 mOsmol/L)
Study: 2106277
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate isoosmolar solution (288 mOsmol/L)
Study: 7373088
Drug: Ribavirin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (1,000 mg/day for five days)
Study: 27633076
Drug: Neurodevelopmental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental treatment (NDT) + Vestibular training (VR)
Study: 25171666
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation treatment in addition to physical therapy (5 days per week for 3 weeks)
Study: 25171666
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (hot pack, facial expression exercises, and massage)
Study: 23176373
Drug: Laser heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laser heat therapy (LHT)
Study: 23176373
Drug: Sham heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham heat therapy (SHT)
Study: 19378542
Drug: Tropisetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (5 mg)
Study: 17274493
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with bisphosphonates and menatetrenone
Study: 10820872
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) with 3 sessions of low energy ESWT (2000 impulses, energy flux density 0.07-0.09 mJ/mm2)
Study: 1814447
Drug: Conservative local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative local therapy
Study: 1814447
Drug: Conservative local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative local treatment
Study: 2985353
Drug: Zinc supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplement
Study: 27022637
Drug: Low-dose subperiosteal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subperiosteal anaesthesia (0.9 ml of articaine with 0.5% epinephrine)
Study: 27022637
Drug: High-dose infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose infiltration anaesthesia (7.2 ml of articaine with 0.5% epinephrine)
Study: 19384124
Drug: Antenatal betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal betamethasone (2x12 mg)
Study: 17442091
Drug: Topical zinc
Normalized name: bacitracin topical zinc compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical zinc oxide 20% ointment
Study: 17442091
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid 15% + lactic acid 15% ointment
Study: 12536697
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg twice daily plus inhaled budelade (half quantity of GINA standard), long-acting aminophyllin 0.2 g twice daily, and inhaled salbutamol when necessary
Study: 12536697
Drug: Inhaled budelade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budelade of GINA standard quantity, long-acting aminophyllin 0.2 g twice daily, and inhaled salbutamol when necessary
Study: 12536697
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg twice daily added to standard treatment for stable asthma
Study: 9430083
Drug: Egg feeding
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg feeding (two eggs daily)
Study: 15915304
Drug: Conservative therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapies
Study: 26943113
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to Daily Occupational Performance (CO‐OP)
Study: 30335720
Drug: Low-Carbohydrate Ketogenic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Carbohydrate Ketogenic Diet (LCKD) (≤50 g or ≤10% daily intake of carbohydrates)
Study: 30335720
Drug: Usual Diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Diet (UD) (>250 g daily intake of carbohydrates)
Study: 18411010
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine 70 microg/h (BUP TDS)
Study: 15927144
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy (BT) consisting of self-control procedures offered in six sessions
Study: 26603250
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy (BT)
Study: 8601845
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no amino acid infusion)
Study: 1981000
Drug: Antacid (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (80 ml of suspension; Maalox 70) administered on the evening before dosing and again 2 h before and 2 h after breakfast
Study: 7012191
Drug: Chlorpheniramine maleate,
Normalized name: Chlorpheniramine Maleate, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate, 4 times daily for one week
Study: 29385005
Drug: 6 hours
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 hours before + immediately before (photobiomodulation therapy [PBMT] applied both 6 hours before and immediately before the test)
Study: 27745820
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (carboplatin and pemetrexed)
Study: 11843722
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.5% bupivacaine hydrochloride
Study: 11843722
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of isotonic sodium chloride solution (Control)
Study: 380614
Drug: Clofibrate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate (2 g/day; period B; 2 months)
Study: 6210878
Drug: Cl2MDP (3200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cl2MDP (3200 mg/day)
Study: 30690293
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (doxorubicin plus ifosfamide)
Study: 17611916
Drug: 3 L
Normalized name: D3 Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 L of polyethylene glycol solution with a soft diet on the preceding day and then 1 L of the solution on the day of colonoscopy (split-dose)
Study: 17611916
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of polyethylene glycol solution with a soft diet on the day before colonoscopy (single-dose)
Study: 16083526
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus Fluvastatin 20 mg
Study: 12394229
Drug: Mannitol infusion
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol infusion (100‐mL 20% mannitol)